Business Wire

Kalray’s Smart Storage Acceleration Card K200-LP™, Now Integrated into Pixitmedia’s Software-Defined Storage Solution Pixstor

Share

Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL),a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce the first outcome of the synergetic combination of its DPU (“Data Processing Unit”) processor-based acceleration card K200-LP™ with newly acquired software-defined storage and data management solutions provider pixitmedia1, a division of Arcapix Holdings Ltd dedicated to the Media & Entertainment markets. The launch of this new joint product comes just months after Kalray's acquisition of Arcapix Holdings Ltd and the new product will be showcased at Flash Memory Summit (USA) in August.

KALRAY’S ACCELERATION CARDS AND DPUs AT THE HEART OF AWARDED PIXITMEDIA’S SOFTWARE-DEFINED STORAGE AND DATA MANAGEMENT SOLUTIONS

Media & Entertainment customers are amongst the most demanding in terms of data storage and data management. The award winning pixstor and ngenea products are deployed by industry leading film studios, broadcasters, postproduction houses and VFX studios, all of whom derive value from the way in which pixitmedia puts the creative user in control of their data. Guaranteed performance, security compliance and flexibility in choice of deployment in a Hybrid, Multi-Cloud world are all a given, but it’s the smart integration with the customer’s workflow and creative pipeline management tools that elevates pixitmedia’s storage credentials.

Just a few months after Kalray’s acquisition of Arcapix Holdings Ltd, Kalray and pixitmedia have combined their technologies to offer a new version of pixstor and ngenea capable of leveraging the Kalray K200-LP™ Smart Storage Acceleration card. This combination of software and hardware offers new perspectives in terms of performance, power consumption, flexibility and, ease of use for pixitmedia’s customers in the Media & Entertainment industry.

KALRAY'S K200-LP™ DEVELOPED FOR HIGH PERFORMANCE STORAGE AND NEXT GENERATION OF DATA MANAGEMENT SOLUTIONS

K200-LP™ is the perfect solution for storage appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per dollar.

Leveraging Kalray’s MPPA® DPU, a new generation of high performance processors tailored to process data-intensive applications, the K200-LP™ Smart Storage Accelerator cards can be programmed to accelerate rich and demanding data services.

Media & Entertainment applications require highly efficient storage and data management solutions while offering a unified, easy to use, collaborative environment for the content creators. In this context, the K200-LP™ card offers new opportunities to improve each step within the typical content workflow .

With the K200-LP™ , we’re able to both consolidate and turbo-charge many of our existing storage-related functions and features that will help us offer even more efficient solutions to our customers. We look forward to exploiting the full power of our MPPA® DPU-based acceleration cards in the future within pixstor and ngenea, be it for accelerating our ability to help customers realize the full value of their existing content with machine learning in pixstor, or reducing the time it takes to shares assets globally with ngenea”, said Barry Evans, Kalray Storage Business CTO and co-founder of Pixitmedia.

The K200-LP™ Smart Storage Accelerator card as well as Pixitmedia DPU-empowered solution will be showcased at Flash Memory Summit, booth #940, from August 2 to 4, 2022, at Santa Clara Convention Center, CA, USA.

ACCELERATING THE MARKET PENETRATION OF KALRAY’S ACCELERATION CARDS

One of the acquisition goals of Arcapix Holdings Ltd, of which pixitmedia is part, by Kalray was to increase growth opportunities, accelerate the commercialization of its technology and products, and leverage cross-selling opportunities. pixitmedia now gives access to new markets opportunities for Kalray, including one of the most demanding and exciting data-intensive industries – Media & Entertainment.

The integration of Kalray’s Cards into pixitmedia’s servers is an important milestone and will contribute to accelerate Kalray’s time-to-market on this specific market.

Eric Baissus, President and CEO of Kalray said: “The synergy with Arcapix is now a reality that customers can experience! We are proud to have a combined solution ready just a few months after the acquisition. It shows both the complementarity of our offering and the unique collaborative mindset that we managed to instill within our company.”

About KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.

Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.

Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com

1pixitmedia is the dedicated division for Media & Entertainment markets of Arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71

ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
+ 33 1 53 67 36 72

PRESS
Loic HAMON
communication@kalrayinc.com
Tel. 04 76 18 90 71

ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release

IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional

PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release

Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom